(Last)

(Street)
NEW YORK

54TH FLOOR

(First)

NY

601 LEXINGTON AVENUE

(Middle)

10022

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasinigton,	D.C.	20040

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

						01.5	ection	30(11) 01 1116	investri	ient C	ompany Ac	1 01 1940								
1. Name and Address of Reporting Person*  ORBIMED ADVISORS LLC						2. Issuer Name and Ticker or Trading Symbol Acutus Medical, Inc. [ AFIB ]									S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner  Officer (size title Check (present))					
					3. Date of Earliest Transaction (Month/Day/Year)  08/10/2020  Officer (give title below)  below)  Other (specify below)															
(Street) NEW YO	RK N	Y					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)     Form filed by One Reporting Person     X Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
		-	Table I - N	on-D	eriva	tive	Seci	urities Ad	cquire	d, D	isposed	of, or Be	eneficia	ally	Owned					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Y		Execution Date		ution Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount Securities Beneficiall Owned Fol Reported		Fo (D)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	Stock			08/1	10/20	20			P		373,50	0 A	\$1	18 373,500		00	I		ee ootnotes <sup>(1)(3)</sup>	
Common	Stock			08/1	10/20	20			P		41,500	) A	\$1	8	41,500		I		ee ootnotes <sup>(2)(3)</sup>	
Common	Stock			08/1	10/20	20			С		3,784,24	40 A	\$0	)	4,157,740		I		ee ootnotes <sup>(1)(3)</sup>	
Common	Stock			08/1	10/20	20			С		1,278,7	18 A	\$0	\$0 1,32		1,320,218			ee ootnotes <sup>(2)(3)</sup>	
			Table II					ities Acc warrants							wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		on Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Securities Underlyi Derivative Security (Instr. 3 and 4)		ng	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		0. wnership orm: irect (D) r Indirect ) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount Number Shares			Transactio (Instr. 4)				
Series B Convertible Preferred Stock	\$0	08/10/2020			С			872,302	(4)		(4)	Common Stock	872,3	02	\$0	0		I	See footnotes <sup>(1)</sup> (3)	
Series B Convertible Preferred Stock	\$0	08/10/2020			С			673,123	(4)		(4)	Common Stock	673,1	23	\$0	0		I See footnot		
Series C Convertible Preferred Stock	\$0	08/10/2020			С			647,582	(4)		(4)	Common Stock	647,5	82	\$0	0		I	See footnotes <sup>(1)</sup> (3)	
Series C Convertible Preferred Stock	\$0	08/10/2020			С			899,985	(4)		(4)	Common Stock	899,9	85	\$0	0		I	See footnotes <sup>(2)(3)</sup>	
Series D Convertible Preferred Stock	\$0	08/10/2020			С			389,116	(4)		(4)	Common Stock	389,1	16	\$0	0		I	See footnotes <sup>(1)</sup> (3)	
Series D Convertible Preferred Stock	\$0	08/10/2020			С			1,202,117	(4)		(4)	Common Stock	1,202,	117	\$0	0		I	See footnotes <sup>(1)</sup> (3)	
Series D Convertible Preferred Stock	\$0	08/10/2020			С			378,733	(4)		(4)	Common Stock	378,7	33	\$0	0		I	See footnotes <sup>(2)(3</sup>	
		Reporting Person*																		

(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*  OrbiMed Capital GP IV LLC							
(Last) 601 LEXINGTON	(First) N AVENUE, 54TF	(Middle) I FLOOR					
(Street) NEW YORK	NY	10022					
(City)	(State)	(Zip)					
Name and Address of Reporting Person*     Orbimed ROF II LLC							
(Last) 601 LEXINGTON	(First) N AVE., 54TH FL	(Middle)					
(Street) NEW YORK	NY	10022					
(City)	(State)	(Zip)					

## **Explanation of Responses:**

- 1. These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV.
- 2. These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II. OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by ORO II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by ORO II.
- 3. Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors.
- 4. Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date.

OrbiMed Advisors LLC, By: /s/
Douglas Coon, Chief
Compliance Officer
OrbiMed Capital GP IV LLC,
By: /s/ Douglas Coon, Chief
Compliance Officer
OrbiMed ROF II LLC, By: /s/

Douglas Coon, Chief 08/12/2020 Compliance Officer

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.